全球胃癌诊断市场

至2030年，全球胃癌诊断市场规模将达30亿美元

全球胃癌诊断市场规模在 2024 年估计为 24 亿美元，预计到 2030 年将达到 30 亿美元，2024 年至 2030 年的复合年增长率为 3.5%。试剂和耗材是报告中分析的细分市场之一，预计复合年增长率为 2.8%，在分析期结束时达到 20 亿美元。在分析期间内，设备部分的复合年增长率预计为 4.8%。

美国市场规模估计为 6.645 亿美元，中国市场预计复合年增长率为 6.3%

预计 2024 年美国胃癌诊断市场价值将达到 6.645 亿美元。作为世界第二大经济体，中国到 2030 年的市场规模预计将达到 5.918 亿美元，在 2024-2030 年分析期间的复合年增长率为 6.3%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为 1.4% 和 2.6%。在欧洲，德国的复合年增长率预计为 1.9%。

全球胃癌诊断市场—主要趋势与驱动因素摘要

为什么胃癌诊断的进步对于早期发现和改善预后至关重要？

早期发现胃癌是一项重大挑战。症状通常在疾病发展后才会出现，导致预后不良和存活率降低。然而，胃癌诊断技术的进步正在改变这种状况，使得人们能够在更早、更容易治疗的阶段发现疾病。因此，人们越来越重视开发能够在胃癌发展之前检测出它的诊断技术。超音波超音波（EUS）和正子断层扫描（PET）等影像技术的进步极大地提高了我们检测胃肿瘤和评估其程度的能力。此外，生物标记检测在诊断过程中变得越来越重要。研究性治疗已经确定了与胃癌相关的各种生物标记物，包括 HER2、p53 和 CA19-9，帮助临床医生更准确地检测胃癌并根据分子图谱制定个人化治疗方案。液态切片是一种分析血液样本中肿瘤 DNA 的非侵入性测试，也是提高诊断能力的突破性方法。这种方法可以提前发现并监测治疗结果，而无需进行侵入性手术。这些创新至关重要，因为它们不仅增加了早期发现的机会，而且提高了治癒治疗的机会，显着改善了患者的治疗效果和存活率。对早期诊断重要性的认识导致对研发的投入增加，从而推动了胃癌检测的进一步创新。

科技创新如何改变胃癌诊断？

技术创新在改变胃癌诊断方面发挥关键作用，使其更有效率、准确且易于获取。其中最重要的发展之一是成像技术的进步。将高清摄影机与窄频成像（NBI）和共聚焦雷射内视镜（CLE）等先进成像技术相结合，提高了内视镜在细胞层面观察胃肿瘤和癌前病变的能力。这些技术可以更早发现异常生长并进行更精确的切片检查，从而提高诊断结果的准确性。此外，人工智慧 (AI) 和机器学习 (ML) 的出现显着增强了成像分析能力，使得能够更快、更准确地识别胃癌。现在可以训练人工智慧演算法来检测人眼可能错过的影像资料中的细微模式，帮助放射科医生和病理学家做出更快、更准确的诊断。次世代定序（NGS）技术的进步使得对胃癌进行全面的基因分析成为可能，分子诊断也得到了快速发展。这种方法可以为肿瘤突变和基因表现提供有价值的见解，有助于指南标靶治疗并改善患者的治疗效果。此外，分析血液样本中循环肿瘤 DNA (ctDNA) 的液态切片技术正在彻底改变非侵入性诊断。该方法提供了一种比传统切片检查技术更简单、侵入性更小的替代方法，预计在最早、最容易治疗的阶段中检测出胃癌。这些技术突破不仅提高了胃癌诊断的速度和准确性，也为更个人化的治疗方案奠定了基础。

推动胃癌诊断解决方案需求的关键因素有哪些？

胃癌诊断解决方案的需求不断增长，这受到多种因素的推动，包括全球胃癌发病率的上升、医疗保健基础设施的进步以及对早期检测和个人化医疗的日益关注。由于饮食、幽门螺旋桿菌感染和遗传易感性等因素，预计许多地区的胃癌发病率将会上升，特别是东亚、中欧和拉丁美洲部分地区。随着世界各地的医疗保健系统认识到早期癌症检测的重要性，对更先进的诊断技术的需求日益增加。此外，液态切片和内视镜筛检等非侵入性和微创诊断技术的日益普及，使得患者和医疗保健专业人员能够更方便、更经济地进行胃癌检测。世界各国政府和医疗机构也在推动改善癌症筛检计划，特别是针对高风险族群，这进一步推动了对胃癌诊断的需求。新兴市场医疗保健基础设施的成长也是一个关键因素。随着开发中地区获得先进的诊断工具，人们更加关注癌症的预防、早期发现和治疗。个人化医疗也是市场驱动力之一，肿瘤基因检测和分子分析已变得十分普遍，以便为每位患者确定最有效的治疗策略。此外，随着社会对胃癌认识的提高，对能够在胃癌扩散之前及早发现胃癌的诊断药物的需求也在不断增长，最终可以改善预后。所有这些因素共同推动了对胃癌诊断解决方案的需求不断增长。

推动胃癌诊断市场成长的关键因素有哪些？

胃癌诊断市场的成长受到多种因素的推动，包括医学进步、全球医疗保健投资的增加以及对该疾病的认识的提高。随着胃癌发生率的不断上升，人们越来越关注能够显着改善预后的早期检测方法，尤其是在高风险地区。早期发现仍然是提高存活率的最重要因素之一，这推动了对先进诊断解决方案的需求激增，这些解决方案可以在疾病发展到后期、更难治疗的阶段之前识别疾病。分子和基因诊断的快速发展也是一个主要驱动力，为研发和临床医生提供了更精确分析肿瘤和为个别患者量身定制治疗方案的工具。液态切片作为一种非侵入性诊断工具的引入，比传统切片检查提供了更早、更安全的检测胃癌的方法，进一步改变了现状。此外，包括人工智慧成像系统和高清内视镜在内的成像技术的进步，为胃组织提供了更准确、更详细的评估，从而可以更好地检测异常生长和早期肿瘤。此外，随着世界各地医疗保健系统的不断现代化，这些尖端诊断工具的使用变得越来越普遍，尤其是在新兴市场。人们认识到胃癌筛检的重要性，尤其是对高风险族群的重要性，导致公共和私营部门都增加了对诊断技术的投资。技术发展以及对利用基因和分子数据来个性化治疗计划的日益关注，正在刺激对能​​够提供更准确和个性化治疗方案的诊断的需求。这些因素正在推动技术创新和应用，预计将推动胃癌诊断市场的持续成长，并有可能改善全球患者的治疗结果和存活率。

部分

产品类型（试剂及耗材、设备）；疾病类型（腺癌、胃淋巴瘤、其他疾病类型）；最终用户（医院、诊断实验室、影像中心）

受访公司范例（42家值得关注的公司）

• Abbott Laboratories
• Agilent Technologies, Inc.
• BD（Becton, Dickinson and Company）
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Biohit Oyj
• CD Genomics
• DiaSorin SpA
• Exalenz Bioscience Ltd.
• FUJIFILM Holdings Corporation
• GeneMatrix Inc.
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Invitae Corporation
• Labcorp Oncology
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• QIAGEN NV

关税影响係数

全球产业分析师根据公司总部所在国家、製造地以及进出口（成品和OEM）预测公司竞争地位的变化。这种复杂且多方面的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、降低盈利、重组供应链等微观和宏观市场动态。

全球产业分析师密切关注世界领先的首席经济学家（14,949）、智库（62）和贸易及产业协会（171）的专家意见，以评估生态系统的影响并应对新的市场现实。各主要国家的专家和经济学家都在关注关税及其对国家的影响。

全球产业分析师预计，这种动盪将在未来两到三个月内平息，新的世界秩序将更加明确地建立。全球产业分析师正在即时追踪这些发展。

2025年4月：谈判阶段

我们四月份的发布将涵盖关税对全球市场整体的影响，并为各地区的市场调整提供指导。我们的预测是基于历史数据和不断发展的市场影响因素。

2025年7月：最终关税调整

免费更新 在各国宣布最终重置后，本公司的客户将在 7 月收到免费更新。最终更新包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业和领域专家的最具影响力的首席经济学家，他们共用了全球经济状况这一前所未有的模式转移的影响。我们的 16,491 多份报告中的大多数都遵循这个基于两阶段里程碑的发布计划。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 比赛

Global Gastric Cancer Diagnostics Market to Reach US$3.0 Billion by 2030

The global market for Gastric Cancer Diagnostics estimated at US$2.4 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Reagents & Consumables, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$664.5 Million While China is Forecast to Grow at 6.3% CAGR

The Gastric Cancer Diagnostics market in the U.S. is estimated at US$664.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$591.8 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Gastric Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Are Advances in Gastric Cancer Diagnostics Crucial for Early Detection and Better Prognosis?

The early detection of gastric cancer is a major challenge, as symptoms often do not appear until the disease has progressed to later stages, leading to poor prognosis and low survival rates. However, advancements in gastric cancer diagnostics are changing the landscape, making it possible to detect the disease at earlier, more treatable stages. As a result, there has been a growing emphasis on developing diagnostic technologies that can identify gastric cancer before it reaches advanced stages. The evolution of imaging techniques, such as endoscopic ultrasound (EUS) and positron emission tomography (PET), has greatly improved the ability to detect gastric tumors and assess their spread. Moreover, biomarker testing is becoming increasingly prominent in the diagnostic process. Researchers have identified a range of biomarkers associated with gastric cancer, including HER2, p53, and CA 19-9, which are helping clinicians to detect the disease more accurately and to personalize treatment plans based on molecular profiles. Liquid biopsy, a non-invasive testing method that analyzes tumor DNA from blood samples, is another breakthrough that is advancing diagnostic capabilities. This approach enables early-stage detection and monitoring of treatment response without the need for invasive procedures. These innovations are crucial as they not only improve the chances of early detection but also offer better chances for curative treatment, significantly enhancing patient outcomes and survival rates. With growing recognition of the importance of early-stage diagnostics, there has been increased investment in research and development, further driving innovation in gastric cancer detection.

How Are Technological Innovations Transforming Gastric Cancer Diagnostics?

Technological innovations are playing a pivotal role in transforming gastric cancer diagnostics, making them more efficient, accurate, and accessible. One of the most significant developments has been the advancement in imaging technologies. Endoscopy, combined with high-definition cameras and advanced imaging techniques like narrow-band imaging (NBI) and confocal laser endomicroscopy (CLE), has improved the ability to visualize gastric tumors and precancerous lesions at the cellular level. These technologies allow for earlier detection of abnormal growths and enable more precise biopsies, improving the accuracy of diagnostic results. Furthermore, the advent of artificial intelligence (AI) and machine learning (ML) has significantly enhanced the analysis of diagnostic imaging, enabling more rapid and accurate identification of gastric cancer. AI algorithms can now be trained to detect subtle patterns in imaging data that may be missed by human eyes, helping radiologists and pathologists make faster and more accurate diagnoses. Molecular diagnostics are also seeing rapid growth, with advances in next-generation sequencing (NGS) technology allowing for comprehensive genetic profiling of gastric cancer. This approach provides valuable insights into tumor mutations and gene expression, which can guide targeted therapy and improve patient outcomes. Additionally, liquid biopsy technology, which involves analyzing circulating tumor DNA (ctDNA) from blood samples, is revolutionizing non-invasive diagnostics. This method offers a simpler, less invasive alternative to traditional biopsy procedures and holds promise for detecting gastric cancer in its earliest, most treatable stages. These technological breakthroughs are not only improving the speed and accuracy of gastric cancer diagnosis but are also laying the groundwork for more personalized treatment options.

What Are the Key Factors Driving the Demand for Gastric Cancer Diagnostic Solutions?

The growing demand for gastric cancer diagnostic solutions is driven by several factors, including the rising global incidence of gastric cancer, advancements in healthcare infrastructure, and the increasing focus on early detection and personalized medicine. The incidence of gastric cancer is expected to rise in many regions, particularly in East Asia, Central Europe, and parts of Latin America, due to factors such as diet, Helicobacter pylori infection, and genetic predisposition. As the global healthcare system recognizes the importance of early cancer detection, the demand for more advanced diagnostic technologies is increasing. Moreover, the increasing adoption of non-invasive and minimally invasive diagnostic techniques, such as liquid biopsy and endoscopic screening, is making gastric cancer detection more accessible and cost-effective for patients and healthcare providers alike. Governments and health organizations worldwide are also pushing for improved cancer screening programs, especially in high-risk populations, which is further fueling demand for gastric cancer diagnostics. The growth of healthcare infrastructure in emerging markets is another key factor. As developing regions gain access to advanced diagnostic tools, there is a greater focus on cancer prevention, early detection, and treatment. Personalized medicine is another driver of the market, as genetic testing and molecular profiling of tumors are becoming more common to identify the most effective treatment strategies for each patient. Furthermore, as public awareness of gastric cancer increases, there is greater demand for diagnostics that can detect the disease in its early stages before it spreads, which ultimately leads to better outcomes. All these factors combined are driving the increasing demand for gastric cancer diagnostic solutions.

What Are the Key Drivers Behind the Growth of the Gastric Cancer Diagnostics Market?

The growth of the gastric cancer diagnostics market is driven by a combination of factors related to medical advancements, increasing global healthcare investment, and rising awareness of the disease. As the prevalence of gastric cancer continues to rise, particularly in high-risk regions, there is an increased focus on early detection methods that can significantly improve prognosis. Early detection remains one of the most important factors in improving survival rates, which has led to a surge in demand for advanced diagnostic solutions that can identify the disease before it progresses to later, harder-to-treat stages. The rapid development of molecular and genetic diagnostics is another key driver, as researchers and clinicians now have the tools to more accurately profile tumors and tailor treatments to individual patients. The introduction of liquid biopsy as a non-invasive diagnostic tool is further transforming the landscape by offering a method for detecting gastric cancer earlier and more safely than traditional biopsies. Additionally, advancements in imaging technology, including AI-powered imaging systems and high-definition endoscopy, are providing more accurate and detailed assessments of gastric tissue, allowing for improved detection of abnormal growths and early-stage tumors. Furthermore, as healthcare systems across the globe continue to modernize, especially in emerging markets, access to these cutting-edge diagnostic tools is becoming more widespread. The increased recognition of the importance of gastric cancer screening, particularly in high-risk populations, has driven both public and private investments in diagnostic technologies. In addition to technological developments, the growing focus on personalized treatment plans that leverage genetic and molecular data has spurred the demand for diagnostics that can provide more precise and tailored treatment options. With these factors driving innovation and adoption, the gastric cancer diagnostics market is poised for continued growth, offering the potential for better outcomes and survival rates for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Gastric Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Reagents & Consumables, Instruments); Disease Type (Adenocarcinoma, Gastric Lymphoma, Other Disease Types); End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Agilent Technologies, Inc.
• BD (Becton, Dickinson and Company)
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Biohit Oyj
• CD Genomics
• DiaSorin S.p.A.
• Exalenz Bioscience Ltd.
• FUJIFILM Holdings Corporation
• GeneMatrix Inc.
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Invitae Corporation
• Labcorp Oncology
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• QIAGEN N.V.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Gastric Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Gastric Cancer Worldwide Drives Increased Demand for Advanced Diagnostic Solutions
  • Growing Awareness of Genetic and Lifestyle Factors Fuels Demand for Comprehensive Gastric Cancer Screening
  • Surge in Investment in Non-Invasive Diagnostic Technologies Expands Market Opportunities for Gastric Cancer Detection
  • Advancements in Liquid Biopsy and Molecular Diagnostics Drive Accuracy and Sensitivity in Early Diagnosis
  • Here's How the Integration of AI and Machine Learning in Diagnostic Tools is Enhancing Gastric Cancer Detection
  • Increased Adoption of Endoscopic Screening Methods Boosts Early Detection Rates and Market Growth
  • Growing Role of Biomarkers in Gastric Cancer Diagnostics Strengthens the Business Case for Precision Medicine
  • Rising Demand for Point-of-Care Diagnostics Expands Access to Early Gastric Cancer Detection in Remote Areas
  • Technological Innovations in Imaging and Optical Methods Enhance Diagnostic Precision and Minimize Invasiveness
  • Rising Focus on Multi-Omic Approaches, Including Genomic and Proteomic Profiling, Drives Diagnostic Advancements
  • Expanding Use of Companion Diagnostics for Personalized Treatment Planning in Gastric Cancer Strengthens Market Potential
  • Rising Focus on Early Detection in High-Risk Populations Creates Opportunities for Targeted Screening Solutions
  • Increased Demand for Integrated Healthcare Solutions and Data Analytics Platforms Enhances Gastric Cancer Diagnostic Accuracy
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gastric Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gastric Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Gastric Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Gastric Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Gastric Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Imaging Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Diagnostic Imaging Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Diagnostic Imaging Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• JAPAN
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• CHINA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• EUROPE
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Gastric Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• FRANCE
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• GERMANY
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• INDIA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Gastric Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Gastric Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• AFRICA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030

IV. COMPETITION